Buprenorphine in Neonatal Abstinence Syndrome.

Authors

Walter K. Kraft, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

1-1-2018

Comments

This article has been peer reviewed. It is the authors' final version prior to publication in Clinical Pharmacology and Therapeutics

Volume 103, Issue 1, January 2018, Pages Pages 112-119.

The published version is available at DOI: 10.1002/cpt.930. Copyright © American Society for Clinical Pharmacology and Therapeutics

Abstract

Infants exposed in utero to opioids will demonstrate a withdrawal syndrome known as neonatal abstinence syndrome (NAS). Buprenorphine is a long-acting opioid with therapeutic use in medication-assisted treatment of opioid dependency in adults and adolescents. Emerging data from clinical trials and treatment cohorts demonstrate the efficacy and safety of sublingual buprenorphine for those infants with NAS who require pharmacologic treatment. Pharmacometric modeling will assist in defining the exposure-response relationships and facilitate dose optimization.

Recommended Citation

Kraft, Walter K., "Buprenorphine in Neonatal Abstinence Syndrome." (2018). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 92.
https://jdc.jefferson.edu/petfp/92

PubMed ID

29105752